## Laurent Coudeville

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8929077/publications.pdf

Version: 2024-02-01

471509 477307 2,271 27 17 29 citations h-index g-index papers 29 29 29 3123 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Dengue Endemicity, Force of Infection, and Variation in Transmission Intensity in 13 Endemic Countries. Journal of Infectious Diseases, 2022, 225, 75-83.	4.0	11
2	Disease transmission and mass gatherings: a case study on meningococcal infection during Hajj. BMC Infectious Diseases, 2022, 22, 275.	2.9	4
3	How did the adoption of wP-pentavalent affect the global paediatric vaccine coverage rate? A multicountry panel data analysis. BMJ Open, 2022, 12, e053236.	1.9	2
4	Large-scale frequent testing and tracing to supplement control of Covid-19 and vaccination rollout constrained by supply. Infectious Disease Modelling, 2021, 6, 955-974.	1.9	6
5	Potential impact of introducing vaccines against COVID-19 under supply and uptake constraints in France: A modelling study. PLoS ONE, 2021, 16, e0250797.	2.5	9
6	The potential impact of dengue vaccination with, and without, pre-vaccination screening. Vaccine, 2020, 38, 1363-1369.	3.8	21
7	Real-World Evidence of Dengue Burden on Hospitals in Mexico: Insights From the Automated Subsystem of Hospital Discharges (Saeh) Database. Revista De Investigacion Clinica, 2019, 71, 168-177.	0.4	6
8	Cost-effectiveness of dengue vaccination in ten endemic countries. Vaccine, 2018, 36, 413-420.	3.8	49
9	Assessment of benefits and risks associated with dengue vaccination at the individual and population levels: a dynamic modeling approach. Expert Review of Vaccines, 2018, 17, 753-763.	4.4	3
10	Impact of a Nonfatal Dengue Episode on Disability-Adjusted Life Years: A Systematic Analysis. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1458-1465.	1.4	20
11	A recombinant live attenuated tetravalent vaccine for the prevention of dengue. Expert Review of Vaccines, 2017, 16, 671-684.	4.4	49
12	Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1898-1903.	1.4	5
13	The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS Medicine, 2016, 13, e1002181.	8.4	178
14	Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America. Journal of Infectious Diseases, 2016, 214, 994-1000.	4.0	41
15	Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine. Vaccine, 2016, 34, 6426-6435.	3.8	35
16	Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine, 2016, 34, 6417-6425.	3.8	42
17	Estimating the Global Burden of Endemic Canine Rabies. PLoS Neglected Tropical Diseases, 2015, 9, e0003709.	3.0	1,008
18	Assessing the Potential of a Candidate Dengue Vaccine with Mathematical Modeling. PLoS Neglected Tropical Diseases, 2012, 6, e1450.	3.0	31

#	Article	IF	CITATION
19	Transmission Dynamics of the Four Dengue Serotypes in Southern Vietnam and the Potential Impact of Vaccination. PLoS ONE, 2012, 7, e51244.	2.5	55
20	Economic Impact of Dengue Illness in the Americas. American Journal of Tropical Medicine and Hygiene, 2011, 84, 200-207.	1.4	339
21	Health Economics of Dengue: A Systematic Literature Review and Expert Panel's Assessment. American Journal of Tropical Medicine and Hygiene, 2011, 84, 473-488.	1.4	140
22	A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum Vaccin, 2010, 6, 841-848.	2.4	30
23	Adult Vaccination Strategies for the Control of Pertussis in the United States: An Economic Evaluation Including the Dynamic Population Effects. PLoS ONE, 2009, 4, e6284.	2.5	63
24	Universal vaccination of children against hepatitis a in Chile: a cost-effectiveness study. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2008, 23, 303-12.	1.1	26
25	The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health–economic analysis. Journal of Gastroenterology, 2007, 42, 152-160.	5.1	45
26	The Economic Value of Childhood Varicella Vaccination in France and Germany. Value in Health, 2005, 8, 209-222.	0.3	47
27	National survey of endodontics in general dental practice in France. European journal of prosthodontics and restorative dentistry, The, 2004, 12, 144-53.	0.4	3